Iqvia (IQV) stock
Last close $245.82 on 2026-11-20 (-1.89%) · Sector: Healthcare
Iqvia helps drug companies and healthcare groups run clinical trials, the studies that test whether new medicines are safe and work. It also sells health data and analytics that customers use to plan research and sales, and it earns most of its money from service fees and data subscriptions.
Iqvia's revenue is growing modestly, at 8.8% over the past year, and it has been solidly profitable, with an operating margin of 12.8%. Over the past year the stock returned 7.7%, which beat the S&P 500's 3.15%, but it is still 13.6% below its 52-week high and 7.9% below its 50-day average. The stock has moved sharply after earnings, rising the day after 2 reports and falling after 2, and insiders sold $1.9 million of stock in the last 90 days while buying none.
Key numbers
- Market cap: $41.1B
- Revenue (last 12 months): $17.31B
- Revenue growth: +8.8%
- Operating margin: 12.8%
- P/E: 29.9
- P/S: 2.4
- Debt to equity: 2.23
- Current ratio: 0.83
Quality score
Overall 21/100 · growth 37 · profitability 35 · financial health 0 · value 12
Performance and risk
1-year return +7.7% vs S&P 500 +3.1% · volatility 40.9% (S&P 500 14.2%) · largest drop -35.9% · beta 0.69
Stock move the day after earnings
- 2026-02-05: -10.7%
- 2026-05-05: +9.6%
- 2026-07-28: +13.9%
- 2026-10-27: -0.7%
Congress trades (90 days)
0 buys, 3 sells
Insider trades (12 months)
Bought $0.0M · sold $39.2M
IQV stock research · IQV options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.